Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Simvastatin Versus Atorvastatin for Improving Mild to Moderate Depression in Post-Coronary Artery Bypass Graft Patients: A Double-Blind, Placebo-Controlled, Randomized Trial Publisher Pubmed



Abbasi SH1, 2 ; Mohammadinejad P3 ; Shahmansouri N1 ; Salehiomran A1 ; Beglar AA1 ; Zeinoddini A3 ; Forghani S4 ; Akhondzadeh S3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Family Health Research Center, Iranian Petroleum Industry Health Research Institute, Tehran, Iran
  3. 3. Psychiatric Research Center, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Razi Vaccine and Serum Research Institute, Karaj, Iran

Source: Journal of Affective Disorders Published:2015


Abstract

Abstract Background A decreased risk of developing depression has been reported among statin users. Aside from their lipid-lowering effects, statins are considered immunomodulatory agents and have protective effects against oxidative stress and inflammation which are well known for their association with depression. The aim of the present study was to compare the probable antidepressant effects of simvastatin and atorvastatin among post-coronary artery bypass graft (CABG) surgery patients with high and low potentials for blood-brain-barrier penetration, respectively. Method Forty-six outpatients who had undergone CABG in the last 6 months and suffered from mild to moderate depression participated in a parallel, double-blind, placebo-controlled trial, and were randomized to undergo 6 weeks of treatment with either simvastatin (20 mg/day) or atorvastatin (20 mg/day). Participants were evaluated using Hamilton depression rating scale (HDRS) at baseline and weeks 3 and 6. The primary outcome was to evaluate the efficacy of simvastatin in improving the depressive symptoms. Result General linear model repeated measures demonstrated significant effect for time×treatment interaction on the HDRS scores [F (1.62, 71.06)=3.41, P=0.048]. There was no significant difference between the treatment groups regarding the adverse events. No one experienced serious adverse event. Limitation The limitations of the present study were its small sample size and the short-term follow-up period. Conclusion Treatment with simvastatin seems to be well tolerated with superior antidepressant effects compared to atorvastatin in post-CABG patients. Long-term outcomes of this practice and its probable influence on other psychological aspects are yet to be investigated in future studies. Trial registration Iranian registry of clinical trials (http://www.irct.ir): IRCT201410271556N68. © 2015 Elsevier B.V.
Related Docs
View other Related Docs
1. Simvastatin As an Adjuvant Therapy to Fluoxetine in Patients With Moderate to Severe Major Depression: A Double-Blind Placebo-Controlled Trial, Journal of Psychopharmacology (2015)
2. Red Yeast Rice As an Adjunct to Sertraline for Treatment of Depression in Patients With Percutaneous Coronary Intervention: Placebo-Controlled Trial, Advances in Integrative Medicine (2018)
3. Rosa Damascena Oil Improves Ssri-Induced Sexual Dysfunction in Male Patients Suffering From Major Depressive Disorders: Results From a Double-Blind, Randomized, and Placebo-Controlled Clinical Trial, Neuropsychiatric Disease and Treatment (2015)
4. L-Carnosine Combination Therapy for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial, Journal of Affective Disorders (2020)
5. Does Oral Administration of Ketamine Accelerate Response to Treatment in Major Depressive Disorder? Results of a Double-Blind Controlled Trial, Journal of Affective Disorders (2018)
6. Palmitoylethanolamide As Adjunctive Therapy in Major Depressive Disorder: A Double-Blind, Randomized and Placebo-Controlled Trial, Journal of Affective Disorders (2018)
7. Effect of Memantine Combination Therapy on Symptoms in Patients With Moderate-To-Severe Depressive Disorder: Randomized, Double-Blind, Placebo-Controlled Study, Journal of Clinical Pharmacy and Therapeutics (2017)
8. Celecoxib for the Treatment of Mild-To-Moderate Depression Due to Acute Brucellosis: A Double-Blind, Placebo-Controlled, Randomized Trial, Journal of Clinical Pharmacy and Therapeutics (2015)
Experts (# of related papers)
View all Related Experts
Shahin Akhondzadeh Basti (33)
Ahmad Ali Noorbala Tafti (6)
Other Related Docs
9. Pentoxifylline for Treatment of Major Depression After Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting: A Randomized, Double-Blind, Placebo-Controlled Trial, Journal of Psychosomatic Research (2021)
10. Therapeutic Effects of Minocycline on Mild-To-Moderate Depression in Hiv Patients: A Double-Blind, Placebo-Controlled, Randomized Trial, International Clinical Psychopharmacology (2016)
11. Crocus Sativus L Versus Citalopram in the Treatment of Major Depressive Disorder With Anxious Distress: A Double-Blind, Controlled Clinical Trial, Pharmacopsychiatry (2017)
12. Metabolic Modeling-Based Drug Repurposing in Statin: An Overview of Mechanistic Approaches in the Management of Craniocerebral Trauma, Journal of Cellular and Molecular Anesthesia (2023)
13. Pioglitazone Adjunctive Therapy for Depressive Episode of Bipolar Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial, Depression and Anxiety (2015)
14. Cilostazol As an Adjunctive Treatment in Major Depressive Disorder: A Pilot Randomized, Double-Blind, and Placebo-Controlled Clinical Trial, Psychopharmacology (2022)
15. Celecoxib Versus Diclofenac in Mild to Moderate Depression Management Among Breast Cancer Patients: A Double-Blind, Placebo-Controlled, Randomized Trial, Annals of Pharmacotherapy (2015)
16. Depression and Inflammation: Is There Any Role for Biomarkers?, Avicenna Journal of Medical Biotechnology (2019)
17. Monoclonal Antibody a Promising Treatment for Depression, Avicenna Journal of Medical Biotechnology (2019)
18. Role of Heart and Its Diseases in the Etiology of Depression According to Avicenna’S Point of View and Its Comparison With Views of Classic Medicine, International Journal of Preventive Medicine (2015)
19. Resveratrol Adjunct Therapy for Negative Symptoms in Patients With Stable Schizophrenia: A Double-Blind, Randomized Placebo-Controlled Trial, International Journal of Neuropsychopharmacology (2020)
20. Riluzole Combination Therapy for Moderate-To-Severe Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial, Journal of Psychiatric Research (2016)
21. Comparison of Vortioxetine and Sertraline for Treatment of Major Depressive Disorder in Elderly Patients: A Double-Blind Randomized Trial, Journal of Clinical Pharmacy and Therapeutics (2020)
22. L-Theanine Combination Therapy With Fluvoxamine in Moderate-To-Severe Obsessive–Compulsive Disorder: A Placebo-Controlled, Double-Blind, Randomized Trial, Psychiatry and Clinical Neurosciences (2023)
23. Efficacy and Safety of Oral Ketamine Versus Diclofenac to Alleviate Mild to Moderate Depression in Chronic Pain Patients: A Double-Blind, Randomized, Controlled Trial, Journal of Affective Disorders (2016)
24. The Effects of Pioglitazone Adjuvant Therapy on Negative Symptoms of Patients With Chronic Schizophrenia: A Double-Blind and Placebo-Controlled Trial, Human Psychopharmacology (2016)
25. Efficacy and Safety of Celecoxib Monotherapy for Mild to Moderate Depression in Patients With Colorectal Cancer: A Randomized Double-Blind, Placebo Controlled Trial, Psychiatry Research (2017)
26. Risperidone Combination Therapy With Propentofylline for Treatment of Irritability in Autism Spectrum Disorders: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Clinical Neuropharmacology (2019)
27. Oxytocin Mitigated the Depressive-Like Behaviors of Maternal Separation Stress Through Modulating Mitochondrial Function and Neuroinflammation, Progress in Neuro-Psychopharmacology and Biological Psychiatry (2017)
28. Efficacy and Safety of Tipepidine As Adjunctive Therapy in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Psychiatry and Clinical Neurosciences (2021)
29. Therapeutic Effects of Saffron (Crocus Sativus) Versus Fluoxetine on Irritable Bowel Syndrome: A Double-Blind Randomized Clinical Trial, Advances in Integrative Medicine (2019)
30. Celecoxib Adjunctive Therapy for Acute Bipolar Mania: A Randomized, Double-Blind, Placebo-Controlled Trial, Bipolar Disorders (2015)
31. Efficacy and Safety of Sulforaphane for Treatment of Mild to Moderate Depression in Patients With History of Cardiac Interventions: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Psychiatry and Clinical Neurosciences (2021)
32. Comparison of Saffron Versus Fluoxetine in Treatment of Mild to Moderate Postpartum Depression: A Double-Blind, Randomized Clinical Trial, Pharmacopsychiatry (2017)
33. Efficacy of Crocus Sativus (Saffron) in Treatment of Major Depressive Disorder Associated With Post-Menopausal Hot Flashes: A Double-Blind, Randomized, Placebo-Controlled Trial, Archives of Gynecology and Obstetrics (2018)
34. Does Statin Use Affect Amyloid Beta Deposition and Brain Metabolism?, CNS Neuroscience and Therapeutics (2023)
35. A Repurposed Drug Screen for Regulating Metabolic Disease: An Overview in the Management of Traumatic Brain Injury; [Una Deteccion De Drogas Reutilizada Para Regular La Enfermedad Metabolica: Una Descripcion General En El Manejo De La Lesion Cerebral Traumatica], Revista Latinoamericana de Hipertension (2022)
36. Studying Neuroprotective Effect of Atorvastatin As a Small Molecule Drug on High Glucose-Induced Neurotoxicity in Undifferentiated Pc12 Cells: Role of Nadph Oxidase, Metabolic Brain Disease (2017)
37. Sulforaphane As an Adjunctive Treatment for Irritability in Children With Autism Spectrum Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Psychiatry and Clinical Neurosciences (2020)
38. 5-Hydroxytryptophan As Adjuvant Therapy in Treatment of Moderate to Severe Obsessive-Compulsive Disorder: A Double-Blind Randomized Trial With Placebo Control, International Clinical Psychopharmacology (2020)
39. Efficacy and Safety of Pentoxifylline Combination Therapy in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, International Clinical Psychopharmacology (2021)
40. Hesperidin Reduces Serum Levels of Triglyceride After Coronary Artery Bypass Graft Surgery, Food Science and Nutrition (2023)
41. Fluvoxamine Combination Therapy With Tropisetron for Obsessive-Compulsive Disorder Patients: A Placebo-Controlled, Randomized Clinical Trial, Journal of Psychopharmacology (2019)
42. Prevalence of Cardiac Depression and Its Related Factors Among Patients With Acute Coronary Syndrome, Asian Journal of Pharmaceutical Research and Health Care (2016)
43. Anxiety- and Depressive-Like Behaviors Are Associated With Altered Hippocampal Energy and Inflammatory Status in a Mouse Model of Crohn's Disease, Neuroscience (2017)
44. Zinc Monotherapy Increases Serum Brainderived Neurotrophic Factor (Bdnf) Levels and Decreases Depressive Symptoms in Overweight or Obese Subjects: A Double-Blind, Randomized, Placebo-Controlled Trial, Nutritional Neuroscience (2015)
45. The Beneficial Effects of Hmg-Coa Reductase Inhibitors in the Processes of Neurodegeneration, Metabolic Brain Disease (2017)